Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lessened its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 32.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 685,447 shares of the medical technology company's stock after selling 336,078 shares during the period. Emerald Advisers LLC owned approximately 0.49% of Alphatec worth $3,811,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Van ECK Associates Corp increased its holdings in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock valued at $99,000 after purchasing an additional 6,998 shares in the last quarter. Stephens Inc. AR increased its holdings in Alphatec by 51.4% in the third quarter. Stephens Inc. AR now owns 21,743 shares of the medical technology company's stock valued at $121,000 after buying an additional 7,382 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Alphatec by 30.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 40,486 shares of the medical technology company's stock valued at $225,000 after acquiring an additional 9,361 shares during the period. Courier Capital LLC boosted its stake in shares of Alphatec by 105.3% during the 3rd quarter. Courier Capital LLC now owns 39,000 shares of the medical technology company's stock worth $217,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in shares of Alphatec in the 3rd quarter worth approximately $107,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Activity at Alphatec

In other news, Director David M. Demski acquired 50,000 shares of the company's stock in a transaction dated Wednesday, August 21st. The stock was acquired at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares in the company, valued at approximately $1,635,460.47. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 22.80% of the stock is owned by insiders.

Alphatec Trading Up 3.1 %

Shares of NASDAQ:ATEC traded up $0.25 during midday trading on Monday, reaching $8.36. The company's stock had a trading volume of 3,842,629 shares, compared to its average volume of 1,955,412. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -6.53 and a beta of 1.31. The business has a 50 day moving average price of $5.82 and a 200 day moving average price of $8.59. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley cut Alphatec from an "overweight" rating to an "equal weight" rating in a report on Thursday, August 1st. Barclays initiated coverage on shares of Alphatec in a research report on Monday, July 8th. They issued an "overweight" rating and a $19.00 price objective on the stock. Lake Street Capital cut their target price on shares of Alphatec from $32.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, September 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 30th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.